Table 7.
Modification of targeting ligands onto the NPs.
| Targeted tissue/organ | Nanocarriers components | Ligands | Ref |
|---|---|---|---|
| Mantle cell lymphoma (MCL) | Dlin-MC3-DMA, cholesterol, DSPC, DMG-PEG, and DSPE-PEG-maleimide, siRNA | Anti-CD38 monoclonal antibodies | [138] |
| Lymphoma | PLGA, HA, siRNA, PLA | CD20 antibodies | [74] |
| Acute myeloid leukemia | siRNA, DOTAP, DOPE, cholesterol, albumin NPs, all-trans retinoic acid (ATRA) | Folate | [139] |
| Liver | siRNA, D SPE-PEG-pPB, DlinMC3, PEG-DMG, DSPC, cholesterol | pPB peptide (C*SRNLIDC*) | [140] |
| Brain, Neurons | siRNA, NL4 peptide and ApoA-I modified dendrigraft PLL (DGL) (generation 3) | NL4 peptide and ApoA-I | [141] |
| Brain, Neurons | DOTAP, siRNA, cholesterol, human transferrin | Tf | [142] |
| Colorectal cancer | SeNPs, siRNA, RGDfC peptide | RGDfC | [143] |
| Prostate cancer | HPAA-PEG-APT, miRNA | Anti-PSMA aptamer | [144] |
| Malignant melanomas | DC-Chol, DOPE, siRNA, AS1411-PEG- DOPE | Aptamer AS1411 | [145] |
| Prostate cancer | siRNA, Adamantane-PEG, Dilysine-cyclodextin | Anisamide | [146] |
| Liver | Epoxide-Based Lipidoids (C12-SPM), DSPC, cholesterol, C16-PEG2000-ceramide, α-galactosyl ceramide, siRNA | galactosylated ceramide | [147] |
Abbreviation: RGDfC: Cyclo (Arg-Gly-Asp-D-Phe-Cys).